Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 6Terminated 3Unknown 2Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Prostatic Neoplasms 1Neoplastic Cells, Circulating 1Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Cisplatin 509Cyclophosphamide 360Carboplatin 352Radiotherapy 350Capecitabine 329Paclitaxel 325Oxaliplatin 324Gemcitabine 319Docetaxel 311Fluorouracil 283Drug Therapy 243apatinib 242Bevacizumab 229camrelizumab 214Etoposide 200Irinotecan 176Doxorubicin 175Leucovorin 161Dexamethasone 160sintilimab 142pembrolizumab 138anlotinib 136Pemetrexed 136Cytarabine 136toripalimab 129Neoadjuvant Therapy 122S 1 (combination) 120Vincristine 119Rituximab 117Radiosurgery 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Interventional × Antiemetics × Clear all
NCT03050866 2021-08-20

CABA-V7

Erasmus Medical Center

Phase 2 Unknown
140 enrolled
Genitourinary

Neoplastic Cells, Circulating, Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT04296240 2020-03-05

Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal Cancer

Peking University Cancer Hospital & Institute

Phase 2 Unknown
119 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡